131036-39-0

Basic information

• Product Name: 3-Bromo-5-Chloro-2-Picoline
• Synonyms: 3-Bromo-5-Chloro-2-Picoline;3-BroMo-5-chloro-2-Methylpyridine
• CAS NO: 131036-39-0
• Molecular Formula: C6H5BrClN
• Molecular Weight: 206.4676
• Mol File: 131036-39-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Bromo-5-Chloro-2-Picoline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-Chloro-2-Picoline(131036-39-0)
• EPA Substance Registry System: 3-Bromo-5-Chloro-2-Picoline(131036-39-0)

Safety Data

• Hazardous Substances Data: 131036-39-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-Chloro-2-Picoline is used as a reagent for the development of picomolar inhibitors of HIV reverse transcriptase. It is particularly effective in the creation of inhibitors featuring bicyclic replacement of the cyanovinylphenyl substructure. This application is significant in the fight against HIV/AIDS, as it aids in the development of potent and specific inhibitors that can effectively target the virus and limit its replication.

Upstream product

• 13061-96-6 dihydroxy-methyl-borane 
• 137628-17-2 2,3-dibromo-5-chloro-pyridine 
• 75-16-1 methylmagnesium bromide 
• 186593-43-1 5-amino-3-bromo-2-methylpyridine 
• 186593-42-0 3-bromo-2-methyl-5-nitropyridine 

Downstream Products

• 1621225-24-8 5-chloro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1227588-49-9 3-bromo-5-chloropyridine-2-carbaldehyde 

Relevant articles and documents

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Compounds and their use as BACE Inhibitors

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.